Another phase II trial of nivolumab, cytarabine and idarubicin in newly diagnosed AML and MDS (NCT02464657) reported that responders had no evidence of MRD at the time of response, and non-responders were more likely to have TP 53 mutations and a higher frequency of BM CD4+ cells co-expressing PD1 and TIM-3 [135]. This evidence concerns the gene CD4 and myelodysplastic syndrome.